Business Wire

SUZANO-S.A.

Share
Lenzing AG: B&C Group and Suzano Enter Into Long-term Partnership

B&C Group (“B&C”) and Suzano S.A. (“Suzano”) today announce that Suzano has entered into a long-term partnership with B&C with respect to its majority stake in Lenzing AG (“Lenzing” or “the company”), the Vienna-listed leading global supplier of cellulosic fibres for the textile and non-wovens industry.

Under the terms of the agreement, Suzano will acquire a 15 percent stake in Lenzing from B&C and the two shareholders will form a long-term syndicate which will hold the majority stake (52.25 percent) in the company. Subject to the closing of the transaction, B&C will hold a 37.25 percent stake in Lenzing and keep the role as controlling member of the new syndicate, with Suzano holding the minority stake of 15 percent. The price per share will be EUR 39.70, with a total acquisition purchase price of EUR 230 million to be fully paid at closing.

As part of the long-term partnership, Suzano has the option to acquire an additional 15 percent stake in the company from B&C until the end of 2028. The agreement also stipulates that B&C will remain a committed long-term shareholder in the company.

With an annual net revenue of more than EUR seven billion in 2023, Brazil-headquartered Suzano is the world’s largest market pulp producer. The company, which is celebrating its centennial year, has a long-standing track record of both operational excellence and commitment to sustainability at all stages of its processes, expertise that will complement Lenzing’s existing business model. Suzano is no direct competitor of Lenzing and has extensive experience in pulp, a raw material with significant importance for Lenzing.

Moving forward, B&C and Suzano plan to support Lenzing’s further development by focusing on driving revenue growth, improving profitability and expanding the company’s international competitiveness.

Walter Schalka, CEO of Suzano, said: “Lenzing is already a leading global supplier of premium cellulosic fibres for the textile and non-wovens industry and we recognize opportunities exist for further growth with its established technology, product range and technical knowledge. Our deep-rooted understanding of pulp production and cost excellence makes Suzano, alongside B&C, an ideal partner for Lenzing as it seeks strengthening its competitive position and global presence. For us, this represents a continuation of our strategy focused on investments which enlarge our addressable market in scalable and competitive business models and move us closer to the end-consumer.”

Wolfgang Hofer, Chairman of B&C Group: “We see this partnership as a win-win-win situation for each party involved. With Suzano, B&C will add a financially strong key shareholder for Lenzing with extensive experience and strong reputation on the international financial markets. Suzano as the leading global pulp producer gains proximity to new markets thanks to this transaction. For Lenzing, this transaction means a commitment of both partners to strengthen Lenzing’s position as a global market leader for sustainable cellulosic fibres.”

In line with the foundation purpose of B&C Private Foundation, the new partners have agreed on a long-term commitment to the existing Lenzing site which will ensure the company’s headquarters, production facilities and key R&D activities remain located in Austria. The partnership also guarantees the continued listing of Lenzing shares on the Vienna stock exchange.

The transaction is subject to approval by the relevant regulatory authorities.

About Suzano S.A.

Suzano is the world’s largest producer of market pulp. Our responsibly grown raw materials are used in products reaching over two billion people in more than 100 countries, including tissue and toilet paper, books, printing and writing paper, diapers and period products, packaging, textiles, and a range of innovative applications that can replace products made from fossil fuels.

Our pulp is made using biomass produced from farmed eucalyptus trees, offering a biodegradable, renewable and recyclable raw material for consumer and industrial use. We plant 1.2 million trees a day on our farms and only harvest what we plant. We manage around 26,000 km2 of land and around 40% of this is protected for permanent conservation, with a zero-deforestation policy across all of our operations.

Suzano’s history goes back over 100 years. We are listed on the B3 stock exchange in Brazil (SUZB3) and the NYSE (SUZ) in the United States.

Learn more at: suzano.com.br/en

About B&C Group

The B&C Private Foundation (www.bcprivatstiftung.at) is an independent foundation. Since its inception in December 2000, its goal has been to foster Austrian entrepreneurship and strengthen Austria’s position as a business hub. B&C acts as a stable core shareholder in Austrian industrial companies through its holding companies, the B&C Group (www.bcgruppe.at). B&C is core shareholder of Lenzing AG and holds majority stakes in Semperit AG Holding (54.2%) and AMAG Austria Metall AG (52.7%). Through B&C Innovation Investments, B&C Group has been investing in tech-driven growth companies since 2016. It currently holds stakes in Awake Mobility, Citrine, Contextflow, Flightkeys, Frequentis, Kinexon, Klarx, Neoom, ParityQC, TriLite und TTTech.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240612561637/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release

Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press release

The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-dateIncome before income taxes of $5.1 million for the quarter and $13.2 million year-to-dateBacklog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income at

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye